分离物 USA-WA1/2020(核酸），NR-1_Vaccinia virus

NR-52347?? Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related Coronavirus 2, Isolate USA-WA1/2020(Nucleic Acids)|SARS-Related Coronavirus 2|Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related Coronavirus 2, Isolate USA-WA1/2020| -60°C or colder |CDCAcknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52347."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. NR-52347 contains a preparation of genomic RNA extracted from heat-inactivated severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 (BEI Resources NR-52286) in buffer, for use as a positive control in qPCR assays. NR-52286 is a preparation of SARS-CoV-2, isolate USA-WA1/2020 that has been inactivated by heating to 65°C for 30 minutes. Each vial contains approximately 100 ?L of inactivated viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

NR-52285?? Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020(Nucleic Acids)|SARS-Related Coronavirus 2|Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020| -60°C or colder |CDCAcknowledgment for publications should read “The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52285."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Genomic RNA was extracted from a preparation of cell lysate and supernatant from Cercopithecus aethiops kidney epithelial cells (Vero E6; ATCC ^? CRL-1586?) infected with SARS-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020. SARS-CoV-2, USA-WA1/2020 was isolated from an oropharyngeal swab from a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Washington, USA. The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced (the isolate - GenBank: MN985325 and after one passage in Vero cells - GenBank: MT020880). The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced after four passages in Vero cells in collaboration with Database for Reference Grade Microbial Sequences (FDA-ARGOS; GenBank: MT246667). BioProject PRJNA716271, Sequencing of SARS-CoV-2 Isolates from BEI Resources, has been published on the NCBI website. The sequences from the BEI Resources SARS-CoV-2 isolates included in the project have been deposited into GenBank (SRA: SRP312598) and the sequence for SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), is available (SAMN18527778). Each vial contains approximately 100 ?L of viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). Each vial of lot 70033320 contains approximately 50 ?L of viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The viral genomic RNA is in a background of cellular nucleic acid and carrier RNA. Innocuity testing was performed on the extracted RNA and results reported on the Certificate of Analysis. The vial should be centrifuged prior to opening. Additional information and tools are available at ViPR (Virus Pathogen Resource).